About IMRIS (OTCMKTS:IMRSQ)
IMRIS Inc. designs, manufactures, and sells image-guided therapy solutions worldwide. The company offers VISIUS Surgical Theatres, a surgical environment that provides intraoperative vision to clinicians to assist in decision-making and enhance precision in treatment. Its VISIUS Surgical Theatre incorporates magnetic resonance imaging, computed tomography, and fluoroscopy into multi-purpose surgical suites to provide intraoperative imaging for specific medical applications by bringing advanced imaging into the operating room (OR). The company sells the VISIUS Surgical Theatres to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular, and cardiovascular markets. It also provides service and extended maintenance contracts, and accessories and disposables. The company was founded in 2005 and is based in Winnipeg, Canada.
Industry, Sector and Symbol
Industry Electromedical equipment
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
EPS (Most Recent Fiscal Year)N/A
Return on EquityN/A
Return on AssetsN/A
IMRIS (OTCMKTS:IMRSQ) Frequently Asked Questions
What is IMRIS's stock symbol?
IMRIS trades on the OTCMKTS under the ticker symbol "IMRSQ."
How were IMRIS's earnings last quarter?
IMRIS (OTCMKTS:IMRSQ) released its quarterly earnings data on Tuesday, October, 28th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.10) by $0.06. The firm earned $6.90 million during the quarter, compared to analysts' expectations of $8.07 million. View IMRIS's Earnings History.
Who are some of IMRIS's key competitors?
Some companies that are related to IMRIS include Medtronic (MDT), SONOVA Hldg AG/ADR (SONVY), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), GETINGE AB/ADR (GNGBY), CONMED (CNMD), NxStage Medical (NXTM), AxoGen (AXGN), Natus Medical (BABY), Cutera (CUTR), Viewray (VRAY), Rockwell Medical (RMTI), Vision Sciences (CGNT) and BioLife Solutions (BLFS).
Who are IMRIS's key executives?
IMRIS's management team includes the folowing people:
- Mr. L. Maurice Holloman, Exec. VP of Operations, Customer Support & Customer Engineering
- Mr. Jeffery Bartels, Principal Accounting Officer and Director of Fin.
- Mr. Meir Dahan, Chief Technology Officer and Exec. VP of R&D
- Dr. Gregory Sorensen, Exec. Chairman (Age 55)
- Mr. Andrew M. Flanagan, Chief Exec. Officer and Pres
Has IMRIS been receiving favorable news coverage?
News articles about IMRSQ stock have trended somewhat positive this week, according to Accern. Accern identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. IMRIS earned a media sentiment score of 0.15 on Accern's scale. They also gave news headlines about the company an impact score of 46.31 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.
How do I buy shares of IMRIS?
Shares of IMRSQ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is IMRIS's stock price today?
One share of IMRSQ stock can currently be purchased for approximately $0.0028.
How big of a company is IMRIS?
IMRIS has a market capitalization of $180,000.00.
How can I contact IMRIS?
IMRIS's mailing address is 5101 SHADY OAK RD, MINNETONKA MN, 55343. The company can be reached via phone at 763-203-6300 or via email at [email protected]
MarketBeat Community Rating for IMRIS (IMRSQ)MarketBeat's community ratings are surveys of what our community members think about IMRIS and other stocks. Vote "Outperform" if you believe IMRSQ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMRSQ will underperform the S&P 500 over the long term. You may vote once every thirty days.